



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/50	A1	(11) International Publication Number: WO 97/41842 (43) International Publication Date: 13 November 1997 (13.11.97)
(21) International Application Number: PCT/US97/07930 (22) International Filing Date: 9 May 1997 (09.05.97) (30) Priority Data: 08/647,171 9 May 1996 (09.05.96) US (71) Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Suite 300, 3700 Market Street, Philadelphia, PA 19104 (US). (72) Inventors: RADIN, Shulamith; 8 Brookview Drive, Voorhees, NJ 08043 (US). DUCHEYNE, Paul; 763 Applegate Lane, Rosemont, PA 19010 (US). FALAIZE, Sylvie; Appartement 303, 31, rue Chevreul, F-69007 Lyon (FR). (74) Agents: ELDERKIN, Dianne, B. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris LLP, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).	(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(54) Title: HOLLOW BONE MINERAL-LIKE CALCIUM PHOSPHATE PARTICLES		
(57) Abstract		
<p>Hollow particles having a shell substantially composed of calcium-phosphate, methods for preparing the same, and methods of use are disclosed. The particles are obtained by differential immersion of silica-based, calcium and phosphate containing glass particles.</p> <div data-bbox="574 1161 1347 1785"></div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HOLLOW BONE MINERAL-LIKE CALCIUM PHOSPHATE PARTICLES

Field of the Invention

This invention relates to particles comprising silica-based, calcium and phosphate containing, glass compositions, and their transformation to calcium-phosphate shells in vitro.

Government Rights

The United States government may have rights to certain aspects of this invention.

10 Background of the Invention

In U.S. Patent No. 5,204,106, issued to Schepers et al., (hereby incorporated by reference) the implantation of bioactive glass granules having the composition: 45% SiO₂, 24.5 % Na₂O, 24.5 % CaO and 6% P₂O₅, and a size range of 280-15 425 μm in diameter into the jaw of beagle dogs is disclosed. With particles of this size range, internal pouches formed in each of the particles and, subsequently, osteoprogenitor cells differentiated to osteoblasts within the pouches, actively laying down bone tissue. Next, bone tissue 20 proliferated from the excavations, surrounded the particles and connected with bone tissue being formed around neighboring particles. Bone tissue was formed within the particle, without being bridged to the lingual or buccal bone plates. At 3 months, bone had grown throughout the surgical 25 defects treated with glass granules. A similar phenomenon was not observed with particles of a larger size range, i.e.,

- 2 -

480-800 micrometers, or a smaller size range, i.e., 210-300 micrometers.

Glass granules of narrow size range (300 - 360 μm) were used in a clinical trial in humans. Schepers et al.,
5 "Bioactive Glass Particles of Narrow Size Range: A New Material for the Repair of Bone Defects," *Implant Dentistry*, 2(3):151-156, 1993, incorporated herein by reference. In this clinical study, 87 patients and 106 maxillo facial defects were treated. At 3 months, the application sites had
10 fully solidified. At six months, no radiological difference between the defect sites and the surrounding bone could be discerned.

It was subsequently discovered that particles in the size range 200-300 micrometers effected the same results if
15 implanted into sites exhibiting a reduced metabolic state, particularly as compared to the maxillo-facial sites. Such sites are found, for example, in the appendicular skeleton, and in certain disease states. U.S. Application Serial No. 08/268,510, hereby incorporated by reference.

20 The *in vivo* event which initiates the reactions leading to the formation of bone throughout the defects is an excavation of the particles. The excavation is the result of physico-chemical reactions taking place in the glass, as well as a cell mediated resorption of the internal reaction layer.
25 Bioactive glass reacts at its surface with the formation of two reaction layers: a silica gel below the surface and a calcium phosphate rich layer at the surface. *In vivo*, pouches of biologically formed calcium phosphate are formed. It is within these pouches that osteoprogenitor cells, which
30 freely float around, undergo differentiation to cells expressing the osteoblastic phenotype. This differentiation does not occur outside these biologically formed calcium phosphate pouches.

Even so, it takes approximately one month for the
35 particles to excavate *in vivo*. A means for further expediting the healing process would be advantageous.

- 3 -

Summary of the Invention

The present invention can further expedite the healing process through the excavation of silica-based glass particles *in vitro*. According to the present invention, silica-based, Ca,P-containing glasses are transformed to hollow CaP-shells *in vitro*, prior to implantation. The silica-based glass granules can be melt- or sol-gel derived. The resultant hollow shells comprise an outer, nanoporous, carbonated amorphous or crystalline CaP-rich layer, with or without remaining silica.

In one aspect, the invention relates to the hollow particles which have been formed *in vitro*.

In another aspect, the invention relates to a method for producing the hollow calcium-phosphate particles according to the invention involving a differential immersion of the particles in solutions which provoke the dissolution of the silicon from the particles.

Brief Description of the Drawings

Figure 1 is a Scanning Electron Micrograph depicting a hollow calcium-phosphate particle according to the invention prepared from melt-derived 45S5 glass.

Figures 2a-c depict the changes in Si, Ca, and P content, respectively, during immersion of sol-gel derived particles as a function of glass composition.

Figure 3 is a Scanning Electron Micrograph depicting a hollow calcium-phosphate particle according to the invention formed from sol-gel derived glass.

Figure 4 depicts changes in Si content during immersion of sol-gel derived particles of S70 glass composition as a function of particle size.

Figure 5 depicts the effect of serum proteins on amount of Si released for S70 sol-gel derived glass particles.

Figure 6 depicts changes in Si content during immersion of melt-derived particles.

Detailed Description

Hollow particles according to the present invention can be used to fill bony defects in sites present throughout the body of vertebrates for stimulating growth and repair.

5 The hollow particles are formed as a result of *in vitro* excavation of silica-based, calcium and phosphate containing glass particles.

As used herein, "silica-based" refers to the inclusion of a silicon oxide in the composition of the glass. Other
10 oxides may also be present.

The melt-derived silica-based, calcium and phosphate containing bioactive glass particles to be excavated according to the present invention can be prepared following, for example, the procedure disclosed in U.S. Patent No.
15 5,204,106, hereby incorporated by reference. The composition for the melt-derived glass is as follows (in weight percent): SiO_2 - 40-60; Na_2O - 10-32; CaO - 10-32; and P_2O_5 - 0-12. Other compounds, and oxides, may also be present, such as described in P. Ducheyne, "Bioglass coatings and bioglass
20 composites as implant materials," *J. Biomed. Mat. Res.*, 19:273-291, 1985, incorporated herein by reference.

The sol-gel derived particles can be prepared following, for example, the procedures disclosed in U.S. Application Serial No. 08/477,585, hereby incorporated by
25 reference. The compositional range for the sol-gel derived glass is as follows (in weight percent): SiO_2 - 60-100; CaO - 3-30; and P_2O_5 - 0-10.

The *in vitro* excavation of the silica-based, Ca,P-containing glass granules and transformation into CaP-shells
30 is achieved by differential immersion of the glass granules in solutions which provoke the dissolution of silicon from the glass matrix. The differential immersion can be achieved by periodic solution exchange in a system in which the solution is static, or by use of a dynamic system in which
35 the immersion solution is continuously supplied as a flow of fresh solution. See, U.S. Patent No. 5,002,890, issued to Dennis R. Morrison on March 26, 1991 for an example of how to

- 5 -

achieve dynamic fluid replenishment in, that case, tissue culture.

The immersion conditions such as, for example, solution composition, duration, number of solution exchanges, material weight to solution volume ratio (W/V), can vary to a great degree. For example, without being limited thereto, the W/V can range from about 0.1 to about 5 mg/ml.

The solution conditions are selected to allow the following events to occur: 1) formation of a surface CaP layer; and 2) continuous dissolution of the silica-network, remaining under the CaP-layer, until about 80 to 100% of the original Si content in the glass is dissolved. In order to stimulate the continuous silica network dissolution, the solution used for the immersion must remain undersaturated with respect to soluble silica. Events 1) and 2) can be achieved by consecutively different solutions. For example, in the case of a glass composed of 100% silica, a calcium-phosphate surface layer must first be formed. This can be accomplished by immersing the glass in solutions saturated in silicon, such as described in U.S. Application Serial No. _____ (our docket UPN-2745), filed concurrently herewith, hereby incorporated by reference.

The following reactions are involved in the transformation of the melt-derived glass granules: hydrolysis and formation of a silica-gel layer; migration of Ca and PO_4 ions from the bulk through the Si-gel to the surface; accumulation of the ions at the surface and formation of a CaP-rich surface; continuous growth of the Si-gel and CaP-rich layers; and continuous silica dissolution. When approximately 80 to 100% of the original Si-content is dissolved, the granules are transformed into voided CaP-shells.

The following reactions are involved in the transformation of sol-gel derived glass granules: loss of soluble silica along with migration of Ca and PO_4 ions through highly porous glass to the surface; leaching of the ions to a solution along with partial accumulation at the

- 6 -

surface; formation of a CaP- surface layer; growth of the CaP-layer along with continuous silica dissolution.

Some solutions which can be used to achieve the glass excavation include, but are not limited to, the following:

- 5 a) water;
- b) ion-free, tris buffer, with an initial pH of from about 6.8 to about 8.0 - for melt-derived bioactive glass;
- c) phosphate buffer solution with an initial pH
10 of from about 6.8 to about 8.0; and
- d) tris or phosphate buffer solutions containing varying concentrations of Ca and PO_4 (HPO_4 or H_2PO_4) with or without addition of
15 varying concentrations of other ions including, but not limited, to Na, K, Cl, CO_3 , and Mg, or their combination.

The only restriction is that the solution be undersaturated in silicon, i.e., solution saturation in silicon is never
20 reached during the period of immersion. It is understood that, with increasing acidity, the absolute concentration of silicon at saturation decreases.

Because the hollowing out is achieved in vitro, the same constraints on particle size are not present as with in
25 vivo excavations. Thus, glass particle size can vary to a large degree. In a preferred embodiment, the particles are from about 50 micrometers to about 5 millimeters -- up to about 1 mm for melt-derived glass; and up to about 5 mm for sol-gel derived glass. With increasing particle size, the
30 treatment duration and/or number of exchanges may also increase.

With increasing stability of the silica-based glass -- such as increasing the amount of network former SiO_2 , increasing the amount of network modifiers that render the
35 network more stable (see Ducheyne, *supra*), or, in the case of melt-derived glass, replacing Na_2O with a more stable alkali oxide -- the duration of treatment and/or the number of

- 7 -

solution exchanges will have to be increased, or the particle size will have to be reduced.

The dissolution of various forms of solid silica in aqueous solutions has been the focus of several studies.

- 5 O'Connor et al., "The kinetics for the solution of silica in aqueous solutions," *J. Phys. Chem.*, 62:1195-8, 1958; and Iler, R.K., The Chemistry of Silica: Solubility, Polymerization, Colloid and Surface Properties, and Biochemistry, Wiley, New York, 1979. It has been established
- 10 that any form of solid silica in contact with aqueous solutions dissolves into monosilicic acid $\text{Si}(\text{OH})_4$ until the solution reaches saturation. By exchanging the immersion solution such that saturation is never reached, the diffusion process is favored and thus dissolution is enhanced. The in
- 15 vitro dissolution behavior during the differential immersion is expected to be similar to that observed in vivo, during which the body fluid is continuously replenished.

- During the differential immersion, the initial silicon content in the particles (either melt-derived or sol-gel
- 20 derived) was completely released in solution, ultimately resulting in the formation of void Ca-P shells. A diffusion of silicon through the Ca-P layer is a possible explanation. We have found that this layer is highly porous.

- The in vitro immersion to transform the silica-based
- 25 glass granules to CaP shells can also be performed in solutions containing various biologically active molecules to produce shells coated with the biologically active molecules to enhance the process of healing and repair. Coating with the various biologically active molecules can be achieved
- 30 during the immersion leading to the granule excavation and transformation into CaP-shells, or can follow the treatment for forming hollow particles as a separate stage. Alternatively, sol-gel derived bioactive glass particles can be prepared having the biologically active molecules
- 35 incorporated in the matrix of the glass using the procedure as disclosed in Application Serial No. 08/477,585, hereby incorporated by reference.

- 8 -

As used herein, the term "about" means approximately \pm 10%.

The term "bony defect", as used herein, refers to regions necessitating growth or repair including, but not
5 limited to, fractures, areas of erosion and degradation, holes resulting from removal of screws and pins, replacements, periodontal applications, and deterioration of bone due to old age or disease.

As used herein, "biologically active molecules" are
10 defined as those organic molecules having an effect in a biological system, whether such system is *in vitro*, *in vivo*, or *in situ*. Biologically active molecules include, but are not limited to, the following categories: growth factors, cytokines, antibiotics, anti-inflammatory agents, analgesics
15 and other drugs, and cell attachment molecules.

The term "antibiotic" includes bactericidal, fungicidal, and infection-preventing drugs which are substantially water-soluble such as, for example, gentamicin, vancomycin, penicillin, and cephalosporins.

20

The term "growth factors" refers, without limitation, to factors affecting the function of cells such as osteogenic cells, fibroblasts, neural cells, endothelial cells, epithelial cells, keratinocytes, chondrocytes, myocytes,
25 cells from joint ligaments, and cells from the nucleus pulposus. Platelet derived growth factors (PDGF), the transforming growth factors (TGF- β), insulin-like growth factors (IGFs), fibroblast growth factors (FGFs), and the bone morphogenetic proteins (BMPs) are examples of growth
30 factors encompassed in the particles according to the present invention.

The term "cell attachment molecules" as used herein includes, but is not limited to, fibronectin, vitronectin, collagen type I, osteopontin, bone sialoprotein
35 thrombospondin, and fibrinogen. Such molecules are important in the attachment of anchorage-dependent cells.

- 9 -

As is disclosed below, the presence of serum proteins in the immersion solution decreases the dissolution rate and, thus, increases the time for immersion and/or number of solution exchanges. A possible explanation is that the
5 adsorption of the proteins on the surface of the glass modifies the surface of the glass in contact with solution.

In addition to their use for filling bone defects, the hollow particles according to the invention can also be used in microgravity tissue culture of anchorage-dependent cells.
10 Some examples of anchorage-dependent cells include, but are not limited to, osteogenic cells, fibroblasts, neural cells, endothelial cells, epithelial cells, keratinocytes, chondrocytes, myocytes, cells from joint ligaments, and cells from the nucleus pulposus. For such cells, the conditions of
15 attachment of the cells to a particular substrate greatly influences their subsequent function.

We have performed a preliminary analysis of the migration of a solid microcarrier in a Rotating-wall vessel (RWV). The following assumptions were introduced: 1) the
20 equations of particle dynamics can be applied to the microcarrier's motion since the bead is infinitesimally small in size compared to surrounding medium; 2) physical properties of both liquid medium and solid particle are constants; 3) the flow field is not affected by the presence
25 of the particle; 4) at time $t > 0$, the fluid is in solid body rotation equal to the angular velocity of the vessel -- secondary flows can be neglected and the fluid flow is steady; and 5) the acceleration of the fluid due to the acceleration of the microcarrier is approximated by the
30 virtual mass (M) concept, where m_b is the mass of microcarrier bead, and m is the mass of the displaced liquid.

The steady-state solution and its stability were determined for two conditions, when the microcarrier is less dense than the surrounding medium ($m > m_b$), and when the liquid
35 medium is less dense than the bead ($m < m_b$). If $m > m_b$, the bead migrates toward an equilibrium position in the inertial frame or travels finally, after decay of the transient motion, on a

- 10 -

concentric circle about the rotation axis in the rotating reference frame. If $m < m_b$, the particle moves away indefinitely. So, in order to maintain a stable system, our model suggests the use of a microcarrier that has an apparent
5 density that is equal to or less than the surrounding medium. The "apparent density" is calculated by dividing the weight of the hollow particle by its volume.

Accordingly, particles which are to serve as carriers for cells in microgravity tissue culture vessels should have
10 an apparent density of about 1.1 g/cm^3 or less. Hollow particles with an apparent density similar to this value can be made using the methods disclosed herein. Such particles possess a further advantage in that the Ca-P layer can serve as a substrate for fibronectin attachment. This molecule is
15 an attachment molecule that serves as the ligand to the cell membrane, leading to cell attachment and, thus, prompting cellular activity. Thus, the particles can be prepared in a manner to incorporate cell attachment molecules in or on the calcium-phosphate shell. Accordingly, use of the particles
20 according to the invention in microgravity culture is not restricted to bone tissue cells, but is universally applicable to anchorage-dependent cells in general including, but not limited to, fibroblasts, neural cells, endothelial, epithelial cells, keratinocytes, chondrocytes, myocytes,
25 hepatocytes, cells from joint ligaments, and cells from the nucleus pulposis.

Example 1

Preparation of Sol-Gels

30 Three types of sol-gel derived particles were synthesized: 100% silica (S100), Vancomycin-silica composites (S100V), and calcium and phosphorus containing silica (S70). S100V contained 1.2 mg of Vancomycin per gram. S70 was composed of: 70% SiO_2 , 25% CaO and 5% P_2O_5 (% by weight).

35 The alkoxides tetramethyl orthosilicate (TMOS - Aldrich Chemical Inc., Milwaukee WI), calcium methoxyethoxide

- 11 -

(CME - Gelest Inc., Tullytown PA) and triethyl phosphate (TEP - Strem Chemical Inc., Newburyport MA) were used as silicon, calcium and phosphorus sources respectively.

S100 and S100V were prepared from a mixture of TMOS
5 and deionized (DI) water in a 1:10 molar ratio. The following procedure was used. Predetermined amounts of TMOS and deionized water, to maintain the molar ratio for the volume prepared, were poured into a beaker which was immediately placed in an ice-cooled ultrasonic bath. For the
10 Vancomycin-containing sol-gel, the amount of water added at this point precludes the amount of water to be added later with the antibiotic. Sonification was performed in the absence of solvent to prevent phase separation. Since sonification provides energy, ice cooling was used to prevent
15 overheating. A small volume of acid catalyst (1N HCl) was then added. Within a few minutes, the mixture became homogenous. Ultrasonic stirring was continued for 20 to 25 minutes and the pH of the solution was measured. The pH did not exceed 3. While the sol was still being stirred and
20 cooled, a previously prepared solution of Vancomycin (Vancoled - Lederle Parentals Inc., Carolina and Puerto Rico) in DI water was added when necessary. The solution was stirred for another five minutes. The sols were cast into preweighed polystyrene vials using a volumetric pipette.
25 Three milliliters were dispensed into each vial. Next, the vials were weighed, sealed, and set aside to allow gelation to occur. The time to gelation was approximately 15 hours.

The gels were left to age for 3 days, with the vials remaining sealed. Afterwards, the gels were exposed to
30 ambient air and dried to 70% loss of the as-cast weight. The disks obtained were then crushed with a ceramic mortar and pestle, and sieved in a sonic sifter to produce particles of two diameter ranges: 210-500 micrometers and 500-710 micrometers. The resulting particles were stored in sealed
35 polystyrene containers at 4 C.

The calcium and phosphorus containing sol was prepared in a glove box under an argon atmosphere. The following

- 12 -

- procedure was used. Prorated amounts of TMOS, CME, and TEP to arrive at a sol-gel composition having a final composition of 70% SiO₂, 25% CaO and 5% P₂O₅ (% by weight), were successively poured in a beaker. The mixture was
- 5 magnetically stirred for about 5 minutes. The sol was cast into preweighed polystyrene vials, 2.23 ml per vial. After casting, the samples were removed from the glove box. To delay gelation, methanol was added in a 1:1 molar ratio with TMOS. The samples were vortexed immediately thereafter.
- 10 Next, 0.1 N acetic acid was added to each sample to simulate the addition of biologically active molecules dissolved in an acidic solution. Gelation occurred within a minute. The remainder of the procedure was the same as for the silica sol-gels.
- 15 The particles were characterized by gas sorption (Quantachrome Autosorb1) and Fourier Transform Infrared Spectroscopy (FTIR, Nicolet 5DXC). The gas sorption analysis indicated that the materials were highly porous. The FTIR spectra revealed absorption bands typical of a silica
- 20 network.

Example 2

Immersion experiments

- The specimens prepared according to Example 1 above were immersed in three solutions: TE, TE supplemented with
- 25 10% serum (vol%), and 100 % serum. The solutions were chosen to address effect of important constituents of the *in vivo* milieu. Immersions were performed in vials. TE is a non-proteinaceous control that contains the electrolyte constituents of human blood plasma in similar concentrations
- 30 (cf. Table I). TE was prepared by dissolving reagent grade NaCl, KCl, NaHCO₃, MgCl₂.6H₂O, MgSO₄.7H₂O, KHPO₄anh. and CaCl₂.2H₂O in a 0.05 M Tris [hydroxymethyl] aminomethane hydrochloride buffered solution. The resulting pH was 7.4 at 37°C. New-born calf serum was used to study the possible
- 35 effects of serum proteins on the *in vitro* behavior of the materials.

Table I
Ionic content of human blood plasma and TE.

Ion	Human blood plasma (mM)	TE (mM)
Ca^{2+}	2.5	2.5
HPO_4^{2-}	1.0	1.0
Na^+	142.0	152.0
Cl^-	103.0	136.0
K^+	5.0	5.0
Mg^{2+}	1.5	1.5
HCO_3^-	27.0	27.0
SO_4^{2-}	0.5	0.5

A differential immersion was effected by exchange with fresh solution at various time points throughout the duration of immersion. In the present example, the samples were exposed to fresh solution after 3, 6, 9, 24, 48, 72, 96, 124 and 168 hours of immersion. These intervals were chosen in an attempt to maintain a maximum concentration of Si in solution less than 2/3 of the saturation concentration. The immersion protocol was intended to reflect the continuous replenishment of body fluid at the implant site. The samples were immersed for up to 7 days.

Three samples were tested per set of conditions. The weight to solution volume ratio was 0.5 mg/ml. The samples were placed in an incubator at 37°C in a 5% CO_2 atmosphere and continuously shaken (200 revolutions/minute). The vials were loosely capped to minimize evaporation without preventing gas exchange.

The testing conditions (i.e., sample, immersion mode, and solution) and the parameters studied are listed in Table II. Upon completion of the selected immersion protocols, the solutions were collected and the retrieved particles were rinsed with ethanol and dried in ambient air.

- 14 -

Table II
Testing conditions

Composition	Particle size	Solution
S100 S100V S70	500-710 μm	TE
S70	210-500 μm	TE
S70	500-710 μm	TE TE+10%serum serum

5 The Si and Ca concentrations were measured by flame
10 atomic absorption spectrophotometry (FAAS, Perkin-Elmer
5100PC). The P concentration was determined using a
colorimetric method (Heinonen et al., "A new and convenient
colorimetric determination of inorganic orthophosphate and
its application to the assay of inorganic pyrophosphate,"
15 *Anal. Biochemistry*, 113:313-7, 1981,) (Molybdenum yellow)
(Pharmacia LKB Ultrospec Plus Spectrophotometer).

The cumulative variation of the Si, Ca, and P
concentration in TE as a function of time of immersion is
shown in Figures 2a-c. The error bars represent the standard
20 deviation of the means. As is evident from Figure 2a, 80% of
the initial silicon content is released from the S70 glass
after 48 hours of immersion and no silicon remained after a
7-day period. Figures 2b and 2c show that the Si dissolution
from S70 is accompanied by the formation of a Ca-P phase, as
25 indicated by a continuous calcium and phosphate uptake from
solution. For S100 glass, 60% of the initial silicon was
released after 72 hours and, again, no silicon remained after
a 7-day period. However, Si dissolution from S100 was not
accompanied by a formation of a Ca-P phase, as indicated by
30 the lack of uptake of calcium and phosphate from solution.
The presence of Vancomycin in S100 did not affect the
dissolution behavior of the composite, as indicated by the
similar release profiles.

To determine the immersion-induced compositional and
35 structural changes, the reacted particles were analyzed with
the same techniques as used for the characterization. In

- 15 -

addition, scanning electron microscopy in combination with energy dispersive x-ray analysis (SEM-EDXA, JEOL T300A) was employed.

FTIR analysis confirmed the formation of a calcium-phosphate material with the characteristics of a crystalline, carbonated hydroxyapatite similar to bone-mineral calcium phosphate.

SEM micrographs of S70 reacted particles show that the particles are transformed into Ca and P containing shells (see Figure 3, X 750). The sample was prepared for SEM examination by fracturing it. As a result, the interior of the particle was exposed. The SEM examination revealed that the particle had been transformed into a shell by the immersion treatment.

EDXA analysis only detected calcium and phosphorus, but no silicon. The Ca/P ratio of the shell as measured by EDXA is 1.5. The shell was approximately 10 μm thick.

Figure 4 shows the silicon release profile S70 particles of two sizes ranges. These results indicate that the dissolution rate increases with decreasing particle size or increasing external surface area. Moreover, the S70 particles of the smaller size range exhibit the same transformation into shell-like shape as found for the larger particles.

Figure 5 shows the dissolution behavior of S70 in TE, TE supplemented with 10% serum, and serum. The presence of serum in the immersion solution decreased the rate of dissolution. Statistical analysis revealed that the release profiles differed significantly among solutions ($p < 0.05$, analysis of variance) except for TE supplemented with 10% serum and 100% serum.

Example 3

Transformation of melt-derived glass 45S5 granules into hollow Ca,P-shells

Granules, 200-300 μm , of melt-derived glass 45S5 (W, %: 45 SiO_2 , 25.5 Na_2O , 24.4 CaO , and P_2O_5), prepared according to the

- 16 -

procedure disclosed in U.S. patent No. 5,204,106, were immersed in tris buffered (pH 7.4 at 37°C) physiological solution with electrolyte content similar to that of the plasma (TE) at a weight/solution volume ratio of 0.5 mg/ml and tested in triplicate in a differential mode at 37°C. The solutions were exchanged at 3,10,24,48,72,96,120, and 144 hours. The total time of immersion was 168 hours.

The concentrations of Si, dissolved from the glass granules, were measured in the post-immersion solutions using flame atomic absorption spectroscopy (Perkin-Elmer, 5100). The post-immersion materials were analyzed using scanning electronmicroscopy (SEM) combined with energy-dispersive X-ray analysis (EDXA). Some of the post-immersion particles were punched with a needle under an optical microscope to expose the inner surfaces.

Figure 6 shows the percentage of Si dissolved from the glass, versus the immersion time. Figure 1 shows the SEM image of the interior surface of a post-immersion particle.

The data, presented in Figure 6, indicate that 80% of the initial Si content in the 45S5 glass was dissolved after 24 hours of the differential immersion (which included 4 solution exchanges by this time), and all the Si content was dissolved by 168 hours.

The SEM photograph shows a hollow particle with a shell about 10 μ m thick. Both the outer layer and the inner surface of the shell comprised a Ca,P-phase as was indicated by EDXA. No remaining Si was detected inside the post-immersion particle.

- 17 -

Thus, the data obtained demonstrate a total transformation of the starting 45S5 glass granules (200-300 μm) into hollow Ca,P-shells during the differential immersion in TE.

- 5 The foregoing examples are meant to illustrate the invention and not to limit it in any way. Those skilled in the art will recognize that modifications can be made which are within the spirit and scope of the invention as set forth in the appended claims.

- 18 -

What is claimed is:

1. A hollow particle having a shell, said shell comprising calcium-phosphate and having an outer diameter of up to about 5 mm.
- 5 2. The particle of claim 1 wherein said shell further comprises silicon.
3. The particle of claim 1 wherein said shell further comprises biologically active molecules.
- 10 4. The particle of claim 2 wherein said biologically active molecules comprise an antibiotic.
5. The particle of claim 3 wherein said antibiotic is vancomycin.
6. The particle of claim 2 wherein said biologically active
15 molecules comprise cell attachment molecules.
7. The particle of claim 2 wherein said biologically active molecules comprise growth factors.
8. The particle of claim 1, said particle having an apparent density of about 1.1 g/cm³.

- 19 -

9. A method for transforming silica-based glass particles into calcium-phosphate shells in vitro comprising immersing silica-based glass particles comprising silica in an aqueous solution undersaturated in soluble silica for a period
5 sufficient to allow substantially all the silica to dissolve from said particles.
10. The method of claim 9 wherein said glass particles are melt-derived.
11. The method of claim 9 wherein said glass particles are
10 sol-gel derived.
12. The method of claim 9 wherein said glass particles further comprise calcium.
13. The method of claim 12 wherein said glass particles further comprise phosphate.
- 15 14. The method of claim 13 wherein said calcium and phosphate are present as a layer on the surface of said glass particles.
15. The method of claim 9 wherein said particles are immersed in said solution until from about 80% to about 100%
20 of the silica has dissolved from said particles.

- 20 -

16. The method of claim 9 wherein the weight to volume ratio of the glass particles to solution is from about 0.1 to about 5 mg/ml.
17. The method of claim 9 wherein the aqueous solution is 5 supplied as a continuous flow.
18. The method of claim 9 wherein said solution further comprises biologically active molecules.
19. The method of claim 18 wherein said biologically active molecules comprise an antibiotic.
- 10 20. The method of claim 19 wherein said antibiotic is vancomycin.
21. The method of claim 18 wherein said biologically active molecules comprise cell attachment molecules.
22. The method of claim 18 wherein said biologically active 15 molecules comprise growth factors.
23. A particle prepared according to the method of claim 9.
24. A method for preparing a particle according to claim 1 comprising immersing silica-based glass particles comprising silica in an aqueous solution undersaturated in soluble

- 21 -

silica for a period sufficient to allow substantially all the silica to dissolve from said particles.

25. The method of claim 24 wherein said glass particles further comprises calcium.

5 26. The method of claim 25 wherein said glass particles further comprises phosphate.

27. The method of claim 26 wherein said calcium and phosphate are present as a layer on the surface of said glass particles.

10 28. A carrier for use in microgravity tissue culture comprising particles according to claim 8.

29. A method for filling a bone defect comprising implanting hollow particles having a shell comprising a carbonated, bone-mineral like, calcium-phosphate layer into said defect,
15 said particles further having an outer diameter of up to about 5 mm.

1/7



FIG.1




FIG. 2A




FIG. 2B

SUBSTITUTE SHEET (RULE 26)

3/7




FIG.2C

4/7




FIG.3

5/7




FIG.4

6/7




FIG.5

7/7




FIG.6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/07930

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 9/50

US CL : 424/489

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/417, 489, 490

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,480,844 A (MATSUI et al.) 02 January 1996, see columns 1-6.	1-29
Y	US 5,024,826 A (LINTON) 18 June 1991, see examples, summary and columns 2-5.	1-29
X	US 4,340,642 A (NETTING et al.) 20 July 1982, see entire Article.	1-3, 9, 12, 13
Y		1-29
Y	US 5,328,955 (RHEE et al.) 12 July 1994, see columns 4-10.	1-29

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

10 JULY 1997

Date of mailing of the international search report

20 AUG 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231Authorized officer
NEIL LEVY

Facsimile No. (703) 305-3230

Telephone No. (703) 308-2351

Form PCT/ISA/210 (second sheet)(July 1992)*

